Assessment of treatment effectiveness in women at high relapse risk for mixed vaginitis
AbstractThe aim of the study was to assess the effectiveness and safety of the combined medicine interferon alpha-2b + metronidazole + fluconazole (Vagiferon®, vaginal suppositories) in the treatment of mixed vaginitis in women at high relapse risk.
Material and methods. The study included 100 women aged from 18 to 49 years with recurrent genital tract infections – mixed vaginitis (aerobic bacteria, candida) accompanied by abnormal vaginal discharge. All patients had risk factors for the recurrent mixed vaginitis development and a history of recurrent vaginal infections (more than 4 relapses per year). Patients received the medicine Vagiferon® intravaginally – one suppository in the morning and one suppository in the evening (before bedtime) for 10 days.
Results. Clinical therapy effectiveness of the given medicine was 99%, microbiological one – 92%. After the treatment completion (in 10–14 days after therapy start) we discovered a significant decrease in the intensity of opportunistic pathogens colonisation in the patients’ vaginal biotope and the appearance of normal biocenosis species (Lactobacillus spp.; p<0.001). Relapses (3 months after treatment) were observed in only 8% of cases. Fast clinical effect (complete absence of complaints in 36–72 hours) was observed in 97% of patients. This result can be contributed to the combined medicine formulation, containing human recombinant interferon alpha-2b with strong immunomodulatory properties. No side or adverse effects have been detected during the use of the given medicine.
Conclusion. The study results showed that the original combined medicine Vagiferon® is a modern medicine of choice for the treatment of vaginitis caused by mixed infections (opportunistic pathogenic bacteria, anaerobic bacteria, yeast-like fungi). The treatment effectiveness (cure rate) with the medicine Vagiferon® in the high relapse risk group for vaginal infections is quite high with rapid clinical effect achieved.
Keywords:vaginitis; mixed vaginitis; vaginal infections; high-risk group; relapses; treatment; combined medicine; interferon alpha-2b; metronidazole; fluconazole; Vagiferon®
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. The concept and design of the study – Kravchenko E.N.; сollection and processing of materials – Krivchik G.V., Kuklina L.V., Sinitsina S.S., Lebed E.M., Muravieva N.G.; statistical data processing – Kuklina L.V.; writing the text – Kravchenko E.N., Kuklina L.V.; editing – Kravchenko E.N.
For citation: Kravchenko E.N., Kuklina L.V., Krivchik G.V., Sinitsina S.S., Muravieva N.G., Lebed E.M. Assessment of treatment effectiveness in women at high relapse risk for mixed vaginitis. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2023; 11 (4): 14–20. DOI: https://doi.org/10.33029/2303-9698-2023-11-4-14-20 (in Russian)
REFERENCES
1. Sobel J.D., Subramanian C., Foxman B., Fairfax M., Gygax S.E. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013; 15 (2): 104–8. DOI: https://doi.org/10.1007/s11908-013-0325-5
2. Qi W., Li H., Wang C., Li H., Zhang B., Dong M., et al. Recent advances in presentation, diagnosis and treatment for mixed vaginitis. Front Cell Infect Microbiol. 2021; 11: 759795. DOI: https://doi.org/10.3389/fcimb.2021.759795 PMID: 34796129; PMCID: PMC8592905.
3. Rivers C.A., Adaramola O.O., Schwebke J.R. Prevalence of bacterial vaginosis and vulvovaginal candidiasis mixed infection in a southeastern American STD clinic. Sex Transm Dis. 2011; 38 (7): 672–4. DOI: https://doi.org/10.1097/OLQ.0b013e31820fc3b8 PMID: 21844715.
4. Fan A., Yue W., Geng N., Zhang X., Wang Y., Xue F. Aerobic vaginitis and mixed infections: comparison of clinical and laboratory data. Arch Gynecol Obstet. 2013; 287 (2): 329–35. DOI: https://doi.org/10.1007/s00404-012-2571-4 Epub 2012 Sept 27. PMID: 23015152.
5. Laniewski P., Ilhan Z.E., Herbst-Kralovetz M.M. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020; 17 (4): 232–50. DOI: https://doi.org/10.1038/s41585-020-0286-z
6. Yu X.Y., Fu F., Kong W.N., Xuan Q.K., Wen D.H., Chen X.Q., et al. Streptococcus agalactiae inhibits the development of Candida albicans hyphae and reduces the TH17 response of the host’s vaginal mucosa. Front Microbiol. 2018; 9: 198. DOI: https://doi.org/10.3389/fmicb.2018.00198
7. Coles P., Jespers V., Hardy L., Krusitti T., Delaney-Moretlve S., Mvaura M., et al. A cross-country cross-examination of the vaginal carriage of group B streptococci (GBS) and E. coli in conditions of resource scarcity: prevalence and risk factors. PLoS One. 2016; 11 (1): e0148052. DOI: https://doi.org/10.1371/journal.pone.0148052
8. Donders G.G.G., Bellen G., Grinkeviciene S., Ruban K., Vieira-Baptista P. Aerobic vaginitis: no longer a stranger. Res Microbiol. 2017; 168 (9–10): 845–58. DOI: https://doi.org/10.1016/j.resmic.2017.04.004
9. Donders G.G., Grinkeviciene S., Ruban K., Bellen G. Vaginal pH and microbiota during maintenance therapy with fluconazole in recurrent vulvovaginal candidiasis (RVVC). Diagn Microbiol Infect Dis. 2020; 97 (2): 115024. DOI: https://doi.org/10.1016/j.diagmicrobio.2020.115024
10. Vorkowski K.A., Bolan G.A. Guidelines for the treatment of sexually transmitted diseases, 2015. MMWR Recomm Rep. 2015; 64 (RR-03): 1–137.
11. Wang Z.L., Fu L.Y., Xiong Z.A., Qin K., Yu T.H., Wu Y.T., et al. Diagnostics and microecological characteristics of aerobic vaginitis in outpatient patients based on preformed enzymes. Taiwan J Obstet Gynecol. 2016; 55 (1): 40–4. DOI: https://doi.org/10.1016/j.tjog.2015.06.012
12. Cohen K.R., Wierzbicki M.R., French A.L., Morris S., Newman S., Reno H., et al. A randomized Lactin-V trial to prevent the recurrence of bacterial vaginosis. N Engl J Med. 2020; 382 (20): 1906–15. DOI: https://doi.org/10.1056/NEJMoa1915254
13. Radzinsky V.E. Everything changes in our age of change. StatusPraesens. Ginekologiya, akusherstvo, besplodniy brak [StatusPraesens. Gynecology, Obstetrics, Barren Marriage]. 2021; 1 (75): 7–9. (in Russian)
14. Kotenko N.V., Borisevich O.O. The use of low-frequency ultrasonic cavitation as an alternative method for the treatment of cervico-vaginal antibiotic-resistant mixed infections. Vestnik vosstanovitel’noy meditsiny [Bulletin of Restorative Medicine]. 2020; 6 (100): 130–7. DOI: https://doi.org/10.38025/2078-1962-2020-100-6-130-137 (in Russian)
15. Posiseeva L.V. Correction of infectious diseases during pregravid preparation in couples. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2016; (4): 131–4. (in Russian)
16. Immunotherapy. Guide for Physicians. In: R.M. Khaitov, R.I. Ataullakhanov. Moscow: GEOTAR-Media, 2018. (in Russian)
17. Boyko E.L., Malyshkina A.I., Vasil’eva T.P., Kovaleva A.V. Vagiferon in the treatment of bacterial vaginosis and bacterial and virus mixed infections in non-pregnant women. Effektivnaya farmakoterapiya. Akusherstvo i ginekologiya. [Effective Pharmacotherapy. Obstetrics and Gynecology]. 2012; (5): 22–5. (in Russian)
18. Aminodova I.P., Posiseeva L.V. Optimization of treatment for genital viral infections. Rossiyskiy vestnik akushera-ginecologa [Russian Bulletin of Obstetrician-Gynecologist]. 2015; 15 (6): 104–8. DOI: https://doi.org/10.17116/rosakush2015156104-108 (in Russian)
19. Kravchenko E.N. Immuno-correcting therapy in comprehensive treatment of nonspecific bacterial vaginitis. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2015; (1): 49–53. (in Russian)
20. Kravchenko E.N., Naboka M.V. Effectiveness of the original combined medicine of recombinant interferon alpha in treatment of bacterial vaginosis. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2016; 15 (2): 9–14. (in Russian)
21. Metelkina S.A., Averina D.M., Kuptsova L.V., Gur’ev D.L. Experience of the combined medication Vagiferon for local use in non-pregnant women with acute nonspecific bacterial vaginitis and candida vaginitis. Meditsinskiy al’manakh [Medical Almanac]. 2015; (4): 89–92. (in Russian)
22. Olina A.A., Meteleva T.A. Current possibilities in the treatment of non-specific vaginal infectious diseases. Rossiyskiy vestnik akushera-ginecologa [Russian Bulletin of Obstetrician-Gynecologist]. 2016; 16 (6): 89–94. (in Russian)
23. Kubanova A.A., Kubanov A.A., Araviyskaya E.A., Samtsov A.V. Federal clinical guidelines. Dermatovenerology 2015: skin diseases. Sexually transmitted infections. 5th ed., revised and additional. Moscow: Business Express, 2016: 768 p. (in Russian)